← Oncology Approval Tracker

FDA DECISION ·

Besponsa

inotuzumab ozogamicin · Pfizer

FDA approvalNew or expanded indicationAcute lymphoblastic leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Children aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

LAMPGEN ANALYSIS

Why it matters

The CD22-directed antibody–drug conjugate expanded into a pediatric salvage setting.

What research teams should watch

Confirm CD22 expression and communicate cumulative exposure and hepatic veno-occlusive disease risk to transplant teams.

PRIMARY RECORDS

Sources